Insane it fell on this reportThe key highlights of the results are as follows:
- Total revenue and other income increased 138% to $83.45M (H1FY2022: $34.97M)
- Direct costs of revenue increased 147% to $74.88M (H1FY2022 $30.41M) in line with expectations and reflective of increased revenue contribution from non-salaried advisers following the Synchron acquisition
- Operating expenses were contained to a 91% increase to $5.68M (H1FY2022: $2.88M) reflective of the success of the Group’s integration program
- The Group’s consolidated EBITDA profit was up 72% to $2.88M (H1FY2022 $1.67M)
- Inclusive of $64K of financing charges associated with premises leases, finance costs were up 65% on the PCP to $313K
- Depreciation and amortisation were up by 82% on the PCP to $458K (H1FY2022 $252K).
- Statutory income tax benefits were $171K (H1FY2022: expense $106K) resulting in a consolidated profit after tax of $2.29M, up 104% on the PCP (H1FY2022: $1.12M)
- Forums
- ASX - By Stock
- WTL
- Ann: Half Yearly Report and Accounts
Ann: Half Yearly Report and Accounts, page-2
Featured News
Add WTL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.4¢ |
Change
0.005(5.62%) |
Mkt cap ! $32.16M |
Open | High | Low | Value | Volume |
9.3¢ | 9.4¢ | 9.3¢ | $4.697K | 50K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 51235 | 8.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.6¢ | 156281 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 51235 | 0.089 |
1 | 125000 | 0.087 |
1 | 86495 | 0.085 |
1 | 85122 | 0.082 |
1 | 200000 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.096 | 156281 | 2 |
0.099 | 10101 | 1 |
0.100 | 395487 | 3 |
0.105 | 77144 | 1 |
0.115 | 77917 | 1 |
Last trade - 12.51pm 15/11/2024 (20 minute delay) ? |
Featured News
WTL (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online